NO20070551L - Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon. - Google Patents
Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.Info
- Publication number
- NO20070551L NO20070551L NO20070551A NO20070551A NO20070551L NO 20070551 L NO20070551 L NO 20070551L NO 20070551 A NO20070551 A NO 20070551A NO 20070551 A NO20070551 A NO 20070551A NO 20070551 L NO20070551 L NO 20070551L
- Authority
- NO
- Norway
- Prior art keywords
- coronavirus
- compositions
- methods
- protein
- vaccine compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58470404P | 2004-06-30 | 2004-06-30 | |
PCT/US2005/023598 WO2006068663A2 (fr) | 2004-06-30 | 2005-06-30 | Compositions de vaccin et procedes permettant de traiter des infections par coronavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070551L true NO20070551L (no) | 2007-03-27 |
Family
ID=36602179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070551A NO20070551L (no) | 2004-06-30 | 2007-01-29 | Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060286124A1 (fr) |
EP (1) | EP1778283A2 (fr) |
JP (1) | JP2008505114A (fr) |
KR (1) | KR20070052273A (fr) |
CN (1) | CN101022827A (fr) |
AU (1) | AU2005319716A1 (fr) |
CA (1) | CA2572389A1 (fr) |
NO (1) | NO20070551L (fr) |
RU (1) | RU2007103343A (fr) |
WO (1) | WO2006068663A2 (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE489968T1 (de) * | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
EP1689433B1 (fr) | 2003-10-22 | 2010-06-30 | ID Biomedical Corporation of Quebec | Compositions et procedes pour activer une immunite innee et une immunite aux allergies |
FR2863890B1 (fr) * | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
NZ578727A (en) * | 2004-06-25 | 2011-03-31 | Brigham & Womens Hospital | Proteosome compositions and methods for treating neurological disorders |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US20070003577A1 (en) * | 2005-06-28 | 2007-01-04 | Kam Yiu W | Purified trimeric S protein as vaccine against severe acute respiratory syndrome virus infections |
BR122015028489B1 (pt) | 2005-12-29 | 2021-10-13 | Boehringer Ingelheim Animal Health Usa Inc | Vacina de combinação multivalente contra pcv2, bem como uso de uma proteína orf2 na preparação da mesma |
EP2371385B1 (fr) | 2005-12-29 | 2015-08-19 | Boehringer Ingelheim Vetmedica, Inc. | Utilisation d'une composition immunogène PCV2 pour diminuer les symptômes cliniques chez les porcs |
EP2859900A1 (fr) | 2006-12-11 | 2015-04-15 | Boehringer Ingelheim Vetmedica, Inc. | Procédé efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis |
CA2670836C (fr) | 2006-12-15 | 2018-09-04 | Boehringer Ingelheim Vetmedica, Inc. | Traitement des porcs avec l'antigene du pcv2 |
EP1941903A1 (fr) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxie et traitement du PRDC |
EP1958644A1 (fr) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prévention et traitement du PCVD subclinique |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
BRPI0821456A2 (pt) * | 2007-12-31 | 2015-06-16 | Boehring Ingelheim Vetmedica Inc | Partícula similar à pcv2 orf2 com inserção de aminoácido estranho |
MX2010007815A (es) | 2008-01-23 | 2010-08-10 | Boehringer Ingelheim Vetmed | Composiciones inmunogenicas de mycoplasma hyopneumoniae contra pcv2 y metodos para producir composiciones de este tipo. |
CA2721366C (fr) * | 2008-04-17 | 2017-06-06 | Elizabeth Ann Vasievich | Stimulation de reponse immunitaire par des enantiomeres de lipides cationiques |
AU2009293595A1 (en) * | 2008-05-23 | 2010-03-25 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
US8877208B2 (en) | 2008-05-23 | 2014-11-04 | The Regents Of The University Of Michigan | Multivalent nanoemulsion vaccines |
EP3020412B1 (fr) * | 2009-06-16 | 2017-10-11 | The Regents of the University of Michigan | Vaccins en nanoémulsion |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
US20130323280A1 (en) * | 2011-01-13 | 2013-12-05 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
EA035265B1 (ru) | 2013-10-02 | 2020-05-21 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы |
KR20170140180A (ko) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도 |
EP3374496A4 (fr) | 2015-11-13 | 2019-07-10 | PDS Biotechnology Corporation | Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
CN113336832B (zh) * | 2020-03-02 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白以及含有该蛋白的疫苗 |
CN111330002B (zh) * | 2020-03-09 | 2020-12-01 | 北京鼎成肽源生物技术有限公司 | 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用 |
CN111217920B (zh) * | 2020-03-10 | 2020-11-17 | 河北精硕生物科技有限公司 | 新冠病毒n-s优势表位融合蛋白、制备方法、应用,及表达蛋白、微生物、应用,试剂盒 |
WO2021183780A1 (fr) * | 2020-03-11 | 2021-09-16 | Ibio, Inc. | Vaccin à base de lichenase contre la covid-19 |
CN113388041B (zh) * | 2020-03-12 | 2024-02-06 | 厦门大学 | 具有融合前早期构象的SARS-CoV-2 S三聚体蛋白及其应用 |
WO2021184391A1 (fr) * | 2020-03-20 | 2021-09-23 | 广州市康润生物科技有限公司 | Procédé de criblage précoce du nouveau coronavirus |
CN111187863A (zh) * | 2020-03-23 | 2020-05-22 | 广州达正生物科技有限公司 | 一种双酶法恒温扩增检测covid-19的试剂盒和检测方法 |
US20210299245A1 (en) * | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
IT202000006754A1 (it) | 2020-03-31 | 2021-10-01 | Diasorin S P A | Saggi per la rivelazione di SARS-CoV-2 |
WO2021201612A1 (fr) * | 2020-03-31 | 2021-10-07 | 주식회사 에스엘백시젠 | Nouvelle composition vaccinale pour la prévention et le traitement du coronavirus |
US11149320B1 (en) | 2020-03-31 | 2021-10-19 | Diasorin S.P.A. | Assays for the detection of SARS-CoV-2 |
EP3892296A1 (fr) * | 2020-04-07 | 2021-10-13 | InnoMedica Holding AG | Composition immunogène comprenant une fraction antigénique et une formulation liposomale, procédé de production de la composition, composition pour une utilisation comme médicament, en particulier pour une utilisation en tant que vaccin |
RU2728939C1 (ru) * | 2020-04-16 | 2020-08-03 | Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) | Применение даларгина для производства средств лечения коронавирусной инфекции covid-19 |
US20230310582A1 (en) * | 2020-04-14 | 2023-10-05 | Duke University | Sars-2 spike protein designs, compositions and methods for their use |
CN116194083A (zh) * | 2020-04-20 | 2023-05-30 | 华润生物医药有限公司 | 抗冠状病毒抗体和其用途 |
FR3110167A1 (fr) * | 2020-05-14 | 2021-11-19 | Faycal Sekkal | SEQUENCES GENOMIQUES ET POLYPEPTIDES DU SARS-CoV-2, POUR UNE DOUBLE UTILISATION VACCINALE ET DE TEST DE L’IMMUNITE CELLULAIRE CUTANEE AU SARS-CoV-2. |
CN111551714B (zh) * | 2020-05-18 | 2023-08-08 | 天津博奥赛斯生物科技股份有限公司 | 一种新型冠状病毒IgM抗体荧光免疫法检测试剂盒 |
US20230203134A1 (en) * | 2020-05-20 | 2023-06-29 | The Trustees Of Columbia University In The City Of New York | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof |
WO2021245611A1 (fr) * | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Protéines modifiées de spicule de coronavirus bêta |
CN113797326B (zh) * | 2020-06-17 | 2024-01-19 | 上海君实生物医药科技股份有限公司 | 一种预防冠状病毒引起疾病的疫苗 |
CN111533812B (zh) * | 2020-06-22 | 2020-10-27 | 艾立克(北京)生物科技有限公司 | 针对sars-cov-2病毒的dna疫苗及其用途 |
US20240009297A1 (en) * | 2020-07-24 | 2024-01-11 | Soligenix, Inc. | Antibody/Adjuvant Compositions and Methods of Immune Response Generation against Coronaviruses |
CN114057843B (zh) * | 2020-08-07 | 2024-02-13 | 清华大学 | 一种预防新型冠状病毒感染covid-19的多肽、免疫原性偶联物及其用途 |
US20230302120A1 (en) * | 2020-08-11 | 2023-09-28 | The Board Of Regents Of The University Of Texas System | Proteins, polynucleotides, and methods for treating coronavirus infection |
JP2023540778A (ja) * | 2020-09-07 | 2023-09-26 | ジーアイ・セル・インコーポレイテッド | Ace2結合力が減少したコロナウイルス由来の受容体結合ドメイン変異体及びこれを含むワクチン組成物 |
CN114164185A (zh) * | 2020-09-11 | 2022-03-11 | 苏州相奕生物技术有限公司 | 一种基于黑猩猩腺病毒表达spike蛋白的新型冠状病毒疫苗 |
US20240000885A1 (en) * | 2020-11-05 | 2024-01-04 | Vanderbilt University | Compositions and methods for targeting the interaction of host myo5b+d and coronavirus m proteins |
CN117098553A (zh) * | 2020-11-11 | 2023-11-21 | 加州理工学院 | 多价载体和相关疫苗组合物 |
MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
US11607449B2 (en) * | 2021-03-16 | 2023-03-21 | King Abdulaziz University | Synthetic plasmid DNA vaccine expressing a codon-optimized SARS-COV-2 spike protein |
WO2022216028A1 (fr) * | 2021-04-08 | 2022-10-13 | 한국생명공학연구원 | Composition vaccinale pour prévenir une maladie infectieuse du coronavirus de type 2 du syndrome respiratoire aigu sévère, ayant une puissance de neutralisation améliorée |
AU2022271918A1 (en) * | 2021-05-10 | 2023-11-30 | Topelia Aust Limited (Acn 652 771 670) | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment |
CN115475239A (zh) * | 2021-05-30 | 2022-12-16 | 中国科学院上海药物研究所 | 一种基于tlr7激动剂偶联肽的新型冠状病毒纳米乳疫苗及其制备 |
WO2023028311A1 (fr) * | 2021-08-27 | 2023-03-02 | Immunophotonics, Inc. | Chitosanes glyqués pour le traitement d'infections virales |
CN114736304A (zh) * | 2021-12-28 | 2022-07-12 | 复旦大学 | 一种融合蛋白、核酸分子、载体、宿主细胞及应用 |
CN116983401A (zh) * | 2023-06-29 | 2023-11-03 | 贝湾生物科技有限公司 | 基于sars1病毒的新冠加强免疫疫苗 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
PT854729E (pt) * | 1995-09-18 | 2004-08-31 | Us Army Med Res Mat Com Usamrm | Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente |
AU2001238478C1 (en) * | 2000-02-15 | 2006-11-09 | Id Biomedical Corporation Of Quebec | Proteosome influenza vaccine |
ATE489968T1 (de) * | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
AU2002365184A1 (en) * | 2001-10-26 | 2003-07-30 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US20050002953A1 (en) * | 2003-05-06 | 2005-01-06 | Jens Herold | SARS-coronavirus virus-like particles and methods of use |
EP1649053A4 (fr) * | 2003-06-18 | 2006-10-18 | Chinese Nat Human Genome Ct Sh | Caracterisation des stades les plus precoces du virus du syndrome respiratoire aigu severe (sras), et applications |
CA2529710A1 (fr) * | 2003-06-20 | 2005-03-10 | Protein Sciences Corporation | Vecteurs d'expression d'immunogenes de sras, compositions contenant de tels vecteurs ou leurs produits d'expression, procedes et dosages pour leur production et leur utilisation |
US20060240515A1 (en) * | 2003-07-21 | 2006-10-26 | Dimitrov Dimiter S | Soluble fragments of the SARS-CoV spike glycoprotein |
-
2005
- 2005-06-30 AU AU2005319716A patent/AU2005319716A1/en not_active Abandoned
- 2005-06-30 EP EP05851200A patent/EP1778283A2/fr not_active Withdrawn
- 2005-06-30 CN CNA2005800223600A patent/CN101022827A/zh active Pending
- 2005-06-30 WO PCT/US2005/023598 patent/WO2006068663A2/fr active Application Filing
- 2005-06-30 JP JP2007519492A patent/JP2008505114A/ja not_active Withdrawn
- 2005-06-30 CA CA002572389A patent/CA2572389A1/fr not_active Abandoned
- 2005-06-30 KR KR1020077002403A patent/KR20070052273A/ko not_active Application Discontinuation
- 2005-06-30 US US11/173,793 patent/US20060286124A1/en not_active Abandoned
- 2005-06-30 RU RU2007103343/13A patent/RU2007103343A/ru unknown
-
2007
- 2007-01-29 NO NO20070551A patent/NO20070551L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101022827A (zh) | 2007-08-22 |
JP2008505114A (ja) | 2008-02-21 |
RU2007103343A (ru) | 2008-08-10 |
WO2006068663A3 (fr) | 2006-11-16 |
EP1778283A2 (fr) | 2007-05-02 |
KR20070052273A (ko) | 2007-05-21 |
AU2005319716A1 (en) | 2006-06-29 |
CA2572389A1 (fr) | 2006-06-29 |
US20060286124A1 (en) | 2006-12-21 |
WO2006068663A2 (fr) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070551L (no) | Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon. | |
NO20090897L (no) | Vaksine | |
AR049176A1 (es) | Vacuna que comprende un pestivirus atenuado | |
IL168584A (en) | West nile virus vaccine | |
NO20072526L (no) | Halvfaste C-klasse immunstimulerende oligonukleotider | |
WO2007117303A3 (fr) | Vaccin combiné comprenant un virus atténué de la diarrhée virale bovine | |
NO20062146L (no) | Nukleosidforbindelser for behandling av virusinfeksjoner | |
DE60024112D1 (de) | Influenzavirus-impfstoffzusammensetzung | |
ATE476983T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege | |
SI1951296T2 (sl) | Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom | |
WO2005116270A3 (fr) | Composition de vaccin contre le virus de la grippe et ses methodes d'utilisation | |
WO2004098491A3 (fr) | Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs | |
MXPA04000680A (es) | Vacuna para virus west nile. | |
MY180698A (en) | Immunization protocol against the 4 dengue serotypes | |
WO2007002470A3 (fr) | Vaccins chimeres inactives et leurs procedes d'utilisation | |
MY169275A (en) | Method of immunization against the four serotypes of dengue | |
DK1471936T3 (da) | HIV-Vaccine og fremgangsmåde til anvendelse | |
WO2006096769A3 (fr) | Utilisation d'inhibiteurs de l'alpha-glucosidase pour traiter les infections par l'alphavirus | |
WO2000057909A3 (fr) | Vaccin a base de virus de dengue-2 attenue | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
WO2004043404A3 (fr) | Procede de conception d'inhibiteurs de la proteine 1 non-structurale de virus grippaux | |
WO2003037265A3 (fr) | Methode de traitement d'infections virales | |
DE60325838D1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
WO2007047916A3 (fr) | Vaccins vih multivalents | |
DK1742656T3 (da) | Hidtil ukendt jordnøddeskindekstrakt som adjuvansvaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |